Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus lutetium-177 octreotate for advanced gastroenteropancreatic neuroendocrine tumors
ACTRN12611000207910Phase 2Not yet recruiting
- Sponsor
- Fremantle Hospital
- Start
- Apr 2011
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus and lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor (2 arms), sponsored by Fremantle Hospital. Primary endpoints: Progression-free survival and Overall survival. Planned start Apr 2011; status: not yet recruiting.
02
Drugs
everolimuslutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on ACTRN12611000207910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000207910.